Search Results

After 7 years at WL/PD and 26 years at Eli Lilly & Co., he retired at the end of 2014 and since then has been writing papers on his final major project at Lilly, a dopamine D1 PAM series that has advanced In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab.

of new drugs targeting specific receptors for various diseases, with Arthur sharing insights on Eli Lilly's

of new drugs targeting specific receptors for various diseases, with Arthur sharing insights on Eli Lilly's

Hit-ID Chemistry Lead - Septerna Junior associate position and a PhD/post-doc level position - Eli Lilly